Covid-19 Tester SourceBio International Planning AIM IPO

(Alliance News) - SourceBio International PLC on Thursday set out plans for a London initial ...

Alliance News 15 October, 2020 | 10:07PM
Email Form

(Alliance News) - SourceBio International PLC on Thursday set out plans for a London initial public offer, but stopped short of offering any further details.

The Nottingham, UK-based integrated laboratory services provider did not clarify how much it will be seeking in its IPO, or at what price its shares will be sold.

SourceBio derives revenue from four core business areas: Healthcare Diagnostics; Genomics; Stability Storage; and Infectious Disease Testing.

Since May of this year, SourceBio has provided Covid-19 testing services.

"These services passed all of the auditing requirements of the NHS and the DHSC in April 2020. It is intended that this offering will potentially provide a broad range of infectious disease testing across the NHS, private healthcare and commercial sectors in the future," the company added.

Prior to the IPO, SourceBio's majority shareholders are Harwood Capital LLP, Continental Investment Partners SA and Lombard Odier Asset Management - holding 33%, 33% and 26%, respectively.

SourceBio's expected admission date is October 29.

By Paul McGowan;

Copyright 2020 Alliance News Limited. All Rights Reserved.

Email Form

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation

By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies